In renal cell carcinoma (RCC) cells, treatment with ADM resulted in the upregulation of ERK1/2 expression, thereby enhancing cancer cell proliferation through the ERK/MAPK signaling pathway [74]. Here, MAPK3 is linked to renal cell carcinoma.